Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

MAGIF

Financiado

Faron leading the way in macrophage guided immunotherapy

Cancer is a leading cause of death in the world despite relentless research to discover new treatments. There were over 18M new cancer cases and 9.6M deaths due to cancer worldwide in 2018. Human suffering due to cancer is devasta... ver más

30/09/2022

FARON PHARMACEUTIC...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

FARON PHARMACEUTICALS OY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 55% 100%

2 Participantes

FARON PHARMACEUTICALS OY

2.50M€ | Lider

ESMALTES DEL SUR

230.90K€ | Participante

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 24 meses Fecha Inicio: 2020-09-24
Fecha Fin: 2022-09-30

Líder del proyecto

FARON PHARMACEUTICALS OY

TRL 4-5

Presupuesto del proyecto 5M€

Descripción del proyecto Cancer is a leading cause of death in the world despite relentless research to discover new treatments. There were over 18M new cancer cases and 9.6M deaths due to cancer worldwide in 2018. Human suffering due to cancer is devastating. The impact and cost of cancer to society is extensive and complex. Faron aims to provide a new solution that could replace several currently used ineffective cancer treatments. Faron is a Finnish biotech company committed to high-quality R&D to fulfil the company’s mission of saving lives. Faron’s game-changing immuno-oncology (IO) treatment CLEVEGEN revolves around a key immunosuppressive molecule named Clever-1 on tumour associated macrophages, responsible for cancer growth and spread. CLEVEGEN is an anti-Clever-1 antibody that brakes the immunosuppressive tolerance of tumours and activates the patient’s immune defences against cancer. The first results from Faron’s first-in-human clinical trial with CLEVEGEN are very positive with early clinical benefits with a switch in patients’ immune profile towards immune stimulation leading to tumour shrinkage in cancer types where nothing has worked before. The early evidence of a clinical response to CLEVEGEN strengthens Faron’s value proposition of it as a break-through cancer treatment. CLEVEGEN has major advantages compared to other IO treatments. Most importantly, patients who would benefit from the treatment can be screened. This would prevent futile treatment and deliver savings in healthcare resources and cost. The CLEVEGEN program is focused on deadly cancer types without effective treatment options and over 3.5M new cases and 2.3M deaths yearly. The market opportunity is clear. With transition to other cancers and the possibility of becoming the first line of therapy due to an exceptional safety profile, the potential up-scale of CLEVEGEN is enormous. There is nothing like CLEVEGEN on the market. CLEVEGEN could secure Faron a world-leading position in the new wave of macrophage guided immunotherapy.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores